Literature DB >> 11096224

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

M Farlow1, R Anand, J Messina, R Hartman, J Veach.   

Abstract

The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon, in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6-12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11096224     DOI： 10.1159/000008243

Source DB:  PubMed          Journal:  Eur Neurol        ISSN： 0014-3022            Impact factor:   1.710


  74 in total

1.  The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach.

Authors:  Grace Wu; Krista L Lanctôt; Nathan Herrmann; Shehnaz Moosa; Paul I Oh
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Long-term cholinesterase inhibitor treatment of Alzheimer's disease.

Authors:  Peter Johannsen
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

3.  Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.

Authors:  Michael Gold; Claire Alderton; Marina Zvartau-Hind; Sally Egginton; Ann M Saunders; Michael Irizarry; Suzanne Craft; Gary Landreth; Ulla Linnamägi; Sharon Sawchak
Journal:  Dement Geriatr Cogn Disord       Date:  2010-08-21       Impact factor: 2.959

Review 4.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

Review 5.  The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.

Authors:  Jaclyn Cappell; Nathan Herrmann; Stephen Cornish; Krista L Lanctôt
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

Review 6.  Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified?

Authors:  Ben Seltzer
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 7.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.

Authors:  Harald Hampel; M-Marsel Mesulam; A Claudio Cuello; Martin R Farlow; Ezio Giacobini; George T Grossberg; Ara S Khachaturian; Andrea Vergallo; Enrica Cavedo; Peter J Snyder; Zaven S Khachaturian
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

8.  Dose-dependent effects of ladostigil on microglial activation and cognition in aged rats.

Authors:  Marta Weinstock; Corina Bejar; Donna Schorer-Apelbaum; Rony Panarsky; Lisandro Luques; Shai Shoham
Journal:  J Neuroimmune Pharmacol       Date:  2013-01-17       Impact factor: 4.147

Review 9.  Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

Authors:  Krista L Lanctôt; Nathan Herrmann; Kenneth K Yau; Lyla R Khan; Barbara A Liu; Maysoon M LouLou; Thomas R Einarson
Journal:  CMAJ       Date:  2003-09-16       Impact factor: 8.262

10.  Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease.

Authors:  Dong-Churl Suh; Simu K Thomas; Elmira Valiyeva; Stephen Arcona; Lien Vo
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.